Ticker

/PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its cobas

Konzernverkäufe stiegen in den ersten sechs Monaten um6% zu konstanten Wechselkursen (CER1; in CHF ausgewiesen -2% und auf USD-Basis28%) aufgrund hoher Nachfrage nach innovativen Medikamenten und Diagnostika. Verkäufe der Division Pharma erhöhten sich um6% (CER; in CHF ausgewiesen -1% und auf USD-Basis8%) aufgrund des kontinuierlich hohen Umsatzwachstums unserer Medikamente in allen Therapiebereichen; die…

AXELIOS 1 delivers a unique combination of accuracy, speed, scalability and cost efficiency, giving laboratories of all sizes the freedom to customise their workflows and explore a wider array of applications. Powered by innovative SBX technology, the platform is capable of end-to-end, same-day whole-genome sequencing in research workflows, with accurate results within hours.

The new VENTANA PTEN (SP218) RxDx Assay fulfils an unmet medical need by helping clinicians identify patients with PTEN protein loss who may benefit from combination treatment with TRUQAP In prostate cancer, PTEN protein loss is associated with faster disease progression and reduced benefit from current standard-of-care treatments1 The FDA approval reinforces Roche's leadership in companion diagnostics and its…

Filing acceptance, under priority review, based on phase III data showing giredestrant reduced the risk of invasive disease recurrence or death by 30% compared with standard-of-care endocrine therapy1Giredestrant represents the first significant advance in adjuvant endocrine therapy in over 20 years1-3Giredestrant has the potential to become a new standard-of-care in the adjuvant setting; more than 90% of…